A share price of Capricor Therapeutics Inc [CAPR] is currently trading at $6.79, down -3.82%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CAPR shares have gain 8.29% over the last week, with a monthly amount drifted -33.30%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Capricor Therapeutics Inc [NASDAQ: CAPR] stock has seen the most recent analyst activity on June 30, 2025, when Alliance Global Partners initiated its Buy rating and assigned the stock a price target of $20. Previously, B. Riley Securities started tracking the stock with Buy rating on June 26, 2025, and set its price target to $21. On May 20, 2025, Roth Capital initiated with a Buy rating and assigned a price target of $31 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $35 on October 21, 2024. Oppenheimer initiated its recommendation with a Outperform and recommended $14 as its price target on May 17, 2024. Cantor Fitzgerald started tracking with a Overweight rating for this stock on January 05, 2024, and assigned it a price target of $8. In a note dated October 26, 2022, Ladenburg Thalmann initiated an Buy rating and provided a target price of $15 on this stock.
Capricor Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $3.52 and $23.40. Currently, Wall Street analysts expect the stock to reach $22 within the next 12 months. Capricor Therapeutics Inc [NASDAQ: CAPR] shares were valued at $6.79 at the most recent close of the market. An investor can expect a potential return of 224.01% based on the average CAPR price forecast.
Analyzing the CAPR fundamentals
Trailing Twelve Months sales for Capricor Therapeutics Inc [NASDAQ:CAPR] were 17.36M which represents -100.00% decline. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -3.3%, Pretax Profit Margin comes in at -3.17%, and Net Profit Margin reading is -3.17%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.62 and Total Capital is -0.44. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.58 points at the first support level, and at 6.37 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.14, and for the 2nd resistance point, it is at 7.49.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Capricor Therapeutics Inc [NASDAQ:CAPR] is 6.55. Also, the Quick Ratio is 6.55, while the Cash Ratio stands at 1.29. Considering the valuation of this stock, the price to sales ratio is 17.88, the price to book ratio is 2.43.
Transactions by insiders
Recent insider trading involved Nippon Shinyaku Co Ltd, 10% Owner, that happened on Sep 20 ’24 when 2.8 million shares were purchased.
